The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. A race to find COVID-19 treatments.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

Drug Discovery World

OCTOBER 18, 2023

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies. Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas.

Therapies 162

Therapies Clinical Trials FDA Approval Virus 162

The Pharma Data

APRIL 15, 2022

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S.

Treatment 52

Treatment Virus Laboratories Engineering 52

Drug Discovery World

AUGUST 2, 2022

Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova. . an estimated 270,000 people were diagnosed with a primary brain tumor in 2020, with a five-year survival rate of only 5%. Official comments . Worldwide,?an survival of ?less

Trials 130

Trials FDA Immune Response Clinical Trials 130

The Pharma Data

NOVEMBER 10, 2020

Antibody Treatment Approved for Emergency Use Against Early COVID-19. 10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. Instead, the treatment should be given as soon as possible after a positive test and within 10 days of developing symptoms.

Treatment 52

Treatment Government Hospitals FDA 52

The Pharma Data

FEBRUARY 1, 2021

HOUSTON, TX, February 01, 2021 /24-7PressRelease/ — It has been just over a year since the COVID-19 virus arrived in the United States, already claiming the lives of over 400,000 Americans. Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients.

Treatment 52

Treatment Hospitals Virus Pharmaceutical Companies 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. It began in May with the $4.9

Science 52

Science Pharmaceuticals Disease FDA Approval 52

The Pharma Data

JULY 23, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. Roche’s Chief Medical Officer and Head of Global Product Development.

Treatment 52

Treatment Virus Clinical Trials Government 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” SAN JOSE, Calif. , About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

MARCH 24, 2021

Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus. billion EUR in 2020 (18.9% Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. of net sales).

Vaccine 52

Vaccine Small Molecule Therapies Disease 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 10:45 UTC. –( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. 2020. for the third quarter of 2020. . for the third quarter of 2020. KENILWORTH, N.J.–(

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. In particular, two COVID-19 pneumonia patients administered at Seoul National University Hospital became virus-free within 10 days by administering hzVSF-v13 twice or three times. Media Contact.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Nature 578 , 229-236 (2020). References Doudna JA. Ylä-Herttuala S.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

NOVEMBER 5, 2020

5, 2020 /PRNewswire/ — Third quarter 2020 revenues increased 32% to $2.29 Third quarter 2020 EYLEA ® U.S. Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07

Production 52

Production FDA FDA Approval Trials 52

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. 22, 2020– Gilead Sciences, Inc. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. FOSTER CITY, Calif.–(BUSINESS

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. With support from a 2020 NIH Director’s Pioneer Award, Veesler will study members of the order Chiroptera.

Virus 52

Virus Immune Response Clinical Trials Vaccine 52

Drug Discovery World

OCTOBER 18, 2022

The idea, I suppose, is to ease the burden on GPs in England by freeing up appointments, so that patients with bacterial infections can access treatments without first needing to see their doctor. The consequences of this action could be severe. AMR is not just a future problem; its impact is being felt right now by healthcare systems.

Doctors 130

Doctors Pharmacy Treatment Virus 130

Drug Target Review

JANUARY 26, 2024

These ACE2-coated particles could be tested as an anti-viral therapeutic, and as sensors for detecting virus particles. Nanovesicles The study co-authors from CFN, Dr Oleg Gang and Dr Feiyue Teng, investigated methods of creating extracellular nanovesicles enriched with decoy human ACE2 for the potential treatment of COVID-19.

Production 114

Production DNA Virus Protein Expression 114

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 52

Trials Treatment Small Molecule Hospitals 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. BOSTON, Oct.

Immune Response 40

Immune Response Clinical Trials Production Therapies 40

The Pharma Data

JUNE 26, 2021

The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. FDA has made Actemra/RoActemra available under an emergency access mechanism called an EUA as a treatment for certain patients with COVID-19.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

OCTOBER 20, 2020

20, 2020 — British scientists are infecting healthy volunteers with COVID-19, in hopes of speeding up vaccine development, TheWashington Post reported Tuesday. Led by scientists at Imperial College London, people in this challenge trial will be guaranteed treatment if they become ill. © 2020 HealthDay. TUESDAY, Oct.

Trials 52

Trials Virus Vaccine Pharmaceutical Companies 52

Drug Discovery World

JANUARY 24, 2023

In the study, published in PLoS Computational Biology , scientists got one step closer to a breakthrough owing to a first-of-its-kind computer model that successfully simulated a clinical trial evaluating the efficacy of multiple treatments for Alzheimer’s disease. How will a treatment fit into the existing competitive landscape?

Clinical Trials 242

Clinical Trials Trials Drugs Treatment 242

The Pharma Data

DECEMBER 3, 2020

4, 2020 11:00 UTC. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e.,

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

DECEMBER 9, 2020

10, 2020 04:32 UTC. The offering is expected to close on or about December 14, 2020, subject to satisfaction of customary closing conditions. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Forward-looking Statements.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Therapies Trials 40

The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — . Food and Drug Administration as part of its review of our Emergency Use Authorization submission, and we continue to focus on completing our ongoing trials evaluating REGN-COV2 for the treatment and prevention of COVID-19.” TARRYTOWN, N.Y. , Regeneron has shared these results with the U.S.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

OCTOBER 23, 2020

23, 2020 — In a Society for Healthcare Epidemiology of America white paper, published online Oct. from the National Institutes of Health in Bethesda, Maryland, and colleagues updated guidance for HCP with HIV and hepatitis, reflecting advances in care and treatment. © 2020 HealthDay. Posted: October 2020.

RNA 52

RNA Virus Vaccine Hospitals 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — For Americans who are worried about the new coronavirus variant that is circulating in Britain, experts in the United States urge everyone to stay calm. “But again, the low mutation rate makes the adaptation of this virus to a vaccine less likely.” ” © 2020 HealthDay. TUESDAY, Dec.

Virus 52

Virus Vaccine Immune Response Treatment 52

The Pharma Data

APRIL 17, 2021

New findings from MS PATHS show that treatment with TYSABRI ® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus ® (ocrelizumab). Real-world data from VUMERITY ® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile.

Treatment 52

Treatment Clinical Trials Trials Therapies 52

The Pharma Data

DECEMBER 15, 2020

15, 2020 — The U.S. Preventive Services Task Force (USPSTF) concludes that screening adults and adolescents at increased risk for hepatitis B virus (HBV) infection has moderate net benefit. © 2020 HealthDay. Posted: December 2020. Professional. USPSTF Recommends Hep B Screen for At-Risk Teens, Adults. TUESDAY, Dec.

Virus 52

Virus Therapies Trials Treatment 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The researchers saw no signs of the virus in the tissue samples, which they said may mean that the damage was not caused by the virus itself.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 16, 2020

17, 2020 11:00 UTC. has sponsored and funded a new FDA Oversight Trial that seeks to restore respiratory function in adults who have suffered lung damage from the COVID-19 virus. Many of these patients, who have been told to get their affairs in order, experience improved lung function and quality of life after treatment.

Trials 52

Trials FDA Treatment Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

3, 2020 17:00 UTC. Under his leadership, the Company has demonstrated the potential of virus-based immunotherapies and developed world class innovative therapies that could be game-changers in the field of cancer treatment. Sandrine has been Chief Financial Officer of Institut Mérieux since March 2020. platform).

Virus 52

Virus Vaccine Treatment Therapies 52